SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-005981 to Longevity Health Holdings, Inc. (XAGE)

Longevity Health Holdings, Inc.
Date: June 5, 2023 · CIK: 0001842939 · Accession: 0000000000-23-005981

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-269773

Date
June 5, 2023
Author
Rajiv Shukla
Form
UPLOAD
Company
Longevity Health Holdings, Inc.

Letter

United States securities and exchange commission logo June 5, 2023 Rajiv Shukla Chief Executive Officer ALPHA HEALTHCARE ACQUISITION CORP III 1177 Avenue of the Americas, 5th Floor New York, New York 10036 Re:ALPHA HEALTHCARE ACQUISITION CORP III Amendment No. 3 to Registration Statement on Form S-4 Filed May 26, 2023 File No. 333-269773 Dear Rajiv Shukla: We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our May 18, 2023 letter. Amendment No. 3 to Registration Statement on Form S-4 Q: What is the expected per share value of the cash consideration to be received by Carmell in the Business Combination?, page 9 1.We note your disclosure describing your table on page 9 as "a calculation of the net cash per New Carmell common stock resulting from the proceeds of the Trust Account." Please amend your disclosure to show the potential impact of redemptions on the per share value of the shares owned by non-redeeming shareholders at each redemption level, taking into account not only the money in the trust account, but the post- transaction equity value of the combined company. Your disclosure should show the impact of certain equity issuances on the per share value of the shares, including the exercises of public and private warrants under each redemption scenario.

FirstName LastNameRajiv Shukla Comapany NameALPHA HEALTHCARE ACQUISITION CORP III June 5, 2023 Page 2 FirstName LastName Rajiv Shukla ALPHA HEALTHCARE ACQUISITION CORP III June 5, 2023 Page 2 Background of the Business Combination Negotiations with Carmell, page 83 2.We note your response to comment 2, and your amended disclosure on page 86, including the following:

•"Pursuant to the Common Stock Purchase Agreement and subject to the satisfaction of the conditions set forth in the Common Stock Purchase Agreement, the Combined Company will have the right, after the Closing Date from time to time, to sell to such an investor up to $25.0 million worth of shares of New Carmell Common Stock subject to certain limitations and conditions set forth in the Common Stock Purchase Agreement;" and

•"The Common Stock Purchase Agreement will provide for a Commitment Fee in the amount of $218,750 payable in shares of New Carmell Common Stock."

Please amend your disclosure to provide additional detail about the conditions set forth in the Common Stock Purchase Agreement, including any discount to market price to be paid by the investor for New Carmell shares. In addition, revise your prospectus summary to describe the agreement, including the commitment fee payable to the investor in the form of commitment shares and any other material terms, and update your estimated ownership percentages upon completion of the business combination throughout your filing to account for the estimated commitment shares. Finally, please include a separate, specific risk factor to address the potential dilutive effect of your equity line agreement with the investor. You may contact Michael Fay at (202) 551-3812 or Brian Cascio at (202) 551-3676 if you have questions regarding comments on the financial statements and related matters. Please contact Jessica Ansart at (202) 551-4511 or Katherine Bagley at (202) 551-2545 with any other questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Jocelyn M. Arel, Esq.

Show Raw Text
United States securities and exchange commission logo
June 5, 2023
Rajiv Shukla
Chief Executive Officer
ALPHA HEALTHCARE ACQUISITION CORP III
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Re:ALPHA HEALTHCARE ACQUISITION CORP III
Amendment No. 3 to Registration Statement on Form S-4
Filed May 26, 2023
File No. 333-269773
Dear Rajiv Shukla:
            We have reviewed your amended registration statement and have the following
comments.  In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.
            Please respond to this letter by amending your registration statement and providing the
requested information.  If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
            After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments.  Unless we note
otherwise, our references to prior comments are to comments in our May 18, 2023 letter.
Amendment No. 3 to Registration Statement on Form S-4
Q: What is the expected per share value of the cash consideration to be received by Carmell in
the Business Combination?, page 9
1.We note your disclosure describing your table on page 9 as "a calculation of the net cash
per New Carmell common stock resulting from the proceeds of the Trust
Account."  Please amend your disclosure to show the potential impact of redemptions on
the per share value of the shares owned by non-redeeming shareholders at each
redemption level, taking into account not only the money in the trust account, but the post-
transaction equity value of the combined company. Your disclosure should show the
impact of certain equity issuances on the per share value of the shares, including the
exercises of public and private warrants under each redemption scenario.

 FirstName LastNameRajiv Shukla
 Comapany NameALPHA HEALTHCARE ACQUISITION CORP III
 June 5, 2023 Page 2
 FirstName LastName
Rajiv Shukla
ALPHA HEALTHCARE ACQUISITION CORP III
June 5, 2023
Page 2
Background of the Business Combination
Negotiations with Carmell, page 83
2.We note your response to comment 2, and your amended disclosure on page 86, including
the following:

•"Pursuant to the Common Stock Purchase Agreement and subject to the satisfaction
of the conditions set forth in the Common Stock Purchase Agreement, the Combined
Company will have the right, after the Closing Date from time to time, to sell to such
an investor up to $25.0 million worth of shares of New Carmell Common Stock
subject to certain limitations and conditions set forth in the Common Stock Purchase
Agreement;" and

•"The Common Stock Purchase Agreement will provide for a Commitment Fee in the
amount of $218,750 payable in shares of New Carmell Common Stock."

Please amend your disclosure to provide additional detail about the conditions set forth in
the Common Stock Purchase Agreement, including any discount to market price to be
paid by the investor for New Carmell shares.  In addition, revise your prospectus summary
to describe the agreement, including the commitment fee payable to the investor in the
form of commitment shares and any other material terms, and update your estimated
ownership percentages upon completion of the business combination throughout your
filing to account for the estimated commitment shares.  Finally, please include a separate,
specific risk factor to address the potential dilutive effect of your equity line agreement
with the investor.
            You may contact Michael Fay at (202) 551-3812 or Brian Cascio at (202) 551-3676 if
you have questions regarding comments on the financial statements and related matters.  Please
contact Jessica Ansart at (202) 551-4511 or Katherine Bagley at (202) 551-2545 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Jocelyn M. Arel, Esq.